Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 18Rituximab 10fludarabine 8ibrutinib 6fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 5Radiotherapy 4Mycophenolic Acid 4Melphalan 4Filgrastim 4Cyclosporine 4Chlorambucil 4Antilymphocyte Serum 4Antigens, CD19 4Valproic Acid 3Sensitivity and Specificity 3Indium 3Immunotherapy, Adoptive 3Busulfan 3Alemtuzumab 3venetoclax 2sargramostim 2obinutuzumab 2navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 2epratuzumab 2Tacrolimus 2Radioimmunodetection 2Psychiatric Rehabilitation 2Pentostatin 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia, Lymphocytic, Chronic, B-Cell × milatuzumab × Clear all
NCT00868478 2010-06-02

The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Kaplan Medical Center

Phase 1/2 Unknown
15 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡